Strs Ohio Boosts Position in Axon Enterprise, Inc $AXON

Strs Ohio boosted its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 12.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 39,287 shares of the biotechnology company’s stock after buying an additional 4,503 shares during the quarter. Strs Ohio’s holdings in Axon Enterprise were worth $22,312,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Caisse Des Depots ET Consignations purchased a new position in Axon Enterprise during the 4th quarter worth approximately $218,000. PFA Pension Forsikringsaktieselskab purchased a new stake in Axon Enterprise in the fourth quarter valued at $23,145,000. Robertson Stephens Wealth Management LLC purchased a new stake in Axon Enterprise in the fourth quarter valued at $11,263,000. Danske Bank A S boosted its holdings in Axon Enterprise by 6.8% in the fourth quarter. Danske Bank A S now owns 58,973 shares of the biotechnology company’s stock valued at $33,493,000 after purchasing an additional 3,753 shares during the last quarter. Finally, Oppenheimer & Co. Inc. boosted its holdings in Axon Enterprise by 11.2% in the fourth quarter. Oppenheimer & Co. Inc. now owns 7,721 shares of the biotechnology company’s stock valued at $4,385,000 after purchasing an additional 777 shares during the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on AXON shares. Robert W. Baird set a $800.00 price target on shares of Axon Enterprise in a report on Wednesday, February 25th. William Blair reaffirmed an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, February 3rd. UBS Group lowered their price target on shares of Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Barclays lowered their price target on shares of Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Finally, TD Cowen lowered their price target on shares of Axon Enterprise from $950.00 to $825.00 and set a “buy” rating on the stock in a report on Wednesday, April 8th. Sixteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average price target of $749.63.

Axon Enterprise Stock Performance

Shares of NASDAQ AXON opened at $402.31 on Monday. The company’s fifty day moving average price is $454.05 and its 200 day moving average price is $532.97. Axon Enterprise, Inc has a 1 year low of $339.01 and a 1 year high of $885.91. The company has a market capitalization of $32.41 billion, a PE ratio of 264.68, a price-to-earnings-growth ratio of 8.59 and a beta of 1.44. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.29 and a current ratio of 2.53.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The firm had revenue of $796.72 million for the quarter, compared to the consensus estimate of $755.29 million. During the same period in the prior year, the firm posted $2.08 earnings per share. The firm’s quarterly revenue was up 38.5% compared to the same quarter last year. On average, research analysts predict that Axon Enterprise, Inc will post 1.41 earnings per share for the current year.

Insider Activity

In related news, insider Isaiah Fields sold 2,000 shares of the stock in a transaction on Friday, February 27th. The shares were sold at an average price of $535.01, for a total transaction of $1,070,020.00. Following the sale, the insider directly owned 55,588 shares of the company’s stock, valued at approximately $29,740,135.88. This represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CAO Jennifer H. Mak sold 1,500 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $573.45, for a total transaction of $860,175.00. Following the sale, the chief accounting officer directly owned 12,240 shares in the company, valued at $7,019,028. This trade represents a 10.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 13,855 shares of company stock valued at $7,109,828 in the last three months. Corporate insiders own 5.70% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.